INMB Q3 2021 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$37M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14,000

Gross Profit

$14,000100.0% margin

Operating Income

-$9M-64435.7% margin

Net Income

-$9M-67557.1% margin

EPS (Diluted)

$-0.55

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$108M

Total Liabilities

$19M

Stockholders' Equity

$88M

Cash & Equivalents

$84M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14,000	$0	—
Gross Profit	$14,000	$0	—
Operating Income	-$9M	-$5M	-87.2%
Net Income	-$9M	-$5M	-100.5%